Chiesi picks a pipeline fight with Novartis, going head-to-head on a big new target for asthma
Early in 2016 the UK’s Atopix Therapeutics was forced to admit that its lead drug, OC459, had failed a mid-stage study for atopic dermatitis. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
